S isomers of α-methyl hydrocinnamic acid for the treatment of blood disorders
View Patent ↗The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia. In some embodiments, the oral pharmaceutical formulation comprising an S-isomer of -α-methyl-hydrocinnamic acid can be used to increase red blood cell proliferation, or increase the proliferation of hemoglobin-expressing cells in a subject in need thereof, e.g., a subject having a blood deficiency such as a subject undergone chemotherapy or radiation exposure or radiation therapy. In some embodiments, a formulation comprising an S-isomer of alpha-methyl-hydrocinnamic acid (ST7S) can be used to simulate myelopiesis or erythropoiesis in a subject in need thereof.
1. An oral pharmaceutical formulation comprising:
(i) a pharmaceutically effective amount of an S isomer of α-methyl-hydrocinnamic acid, or a pharmaceutically acceptable salt thereof; and
(ii) a pharmaceutically acceptable carrier or diluent,
wherein the oral pharmaceutical composition comprises less than 6% of the R isomer of α-methyl-hydrocinnamic acid and wherein the oral pharmaceutical formulation is in solution or a dry solid.
2. The oral pharmaceutical formulation of claim 1 , wherein the formulation is in solution as a dispersion, mixture, liquid, spray, or capsule.
3. The oral pharmaceutical formulation of claim 1 , wherein the formulation is a dry solid as a powder, pill, tablet, or capsule.
4. The oral pharmaceutical formulation of claim 1 , wherein the formulation is a sustained release formulation.
5. The oral pharmaceutical formulation of claim 1 , wherein the formulation is an enteric coated formation.
6. The oral pharmaceutical formulation of claim 5 , wherein the enteric coated formation comprises an enteric polymer casing for sustained release.
7. A method for treating a blood disorder in a subject comprising administering to the subject an oral pharmaceutical composition comprising:
(i) a pharmaceutically effective amount of an S isomer of α-methyl-hydrocinnamic acid, or a pharmaceutically acceptable salt thereof; and
(ii) a pharmaceutically acceptable carrier or diluent,
wherein the oral pharmaceutical composition comprises less than 6% of the R isomer of α-methyl-hydrocinnamic acid and wherein the oral pharmaceutical composition is in solution or a dry solid, and wherein the oral pharmaceutical composition is administered to the subject by oral administration, thereby treating the blood disorder in the subject.
8. The method of claim 7 , further comprising monitoring hemoglobin-expressing cells to ensure that cell proliferation is stimulated, and that cell viability is not significantly decreased.
9. The method of claim 7 , further comprising obtaining the S isomer of α-methyl-hydrocinnamic acid.
10. The method of claim 7 , wherein the composition is in solution as a dispersion, mixture, liquid, spray, or capsule.
11. The method of claim 7 , wherein the composition is a dry solid as a powder, pill, tablet, or capsule.
12. The method of claim 7 wherein the blood disorder is selected from the group consisting of: hemoglobinopathy, thalassemia, neutropenia, thrombocytopenia, anemia, white blood cell deficiencies, or aplastic anemia.
13. The method of claim 7 , wherein the subject has been exposed to radiation, radiation therapy, chemotherapy, or transplantation.